BCX 1470

Drug Profile

BCX 1470

Latest Information Update: 30 Sep 1999

Price : $50

At a glance

  • Originator BioCryst Pharmaceuticals; University of Alabama; University of Alabama at Birmingham
  • Class Anti-inflammatories; Antihaemorrhagics
  • Mechanism of Action Complement C1 inhibitors; Complement factor D inhibitors; Kallikrein inhibitors; Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Blood coagulation disorders; Reperfusion injury

Most Recent Events

  • 30 Sep 1999 Discontinued-I for Reperfusion injury in USA (IV)
  • 30 Sep 1999 Discontinued-I for Coagulation disorders in USA (IV)
  • 27 Oct 1998 Phase-I clinical trials for Reperfusion injury in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top